Also known as: OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $17 billion across public and private markets. Founded in 1989, it invests globally in biopharmaceuticals, medical devices, diagnostics, healthcare IT, and services. The firm is headquartered in New York City with offices in multiple international locations.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Immunic announced an oversubscribed private placement of up to $400 million to complete phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive MS, and transition to a commercial organization.
Immunic announced an oversubscribed private placement of up to $400 million to complete Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive MS, and transition into a commercial organization.
